Low incidence of NOTCH1 mutations in GATA3low ETP-ALL will likely render NOTCH-targeted therapies (e.g., γ-secretase inhibitors) ineffective. This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.